What is the recommended management of asthma in an adult?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 22, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

How to Treat Asthma in an Adult

All adults with asthma should receive inhaled corticosteroid (ICS)-containing treatment, and short-acting beta2-agonist (SABA)-only treatment is strongly contraindicated. 1, 2

Preferred Treatment Approach: Track 1 (Anti-Inflammatory Reliever Strategy)

The most current evidence supports using low-dose ICS-formoterol as both maintenance and reliever therapy across all severity levels 1, 2. This approach reduces severe exacerbations by more than 60% compared to SABA-only treatment 2.

Stepwise Treatment Algorithm

Step 1 (Mild Intermittent):

  • As-needed low-dose ICS-formoterol only (budesonide-formoterol 160/4.5 μg)
  • Use when symptoms occur less than twice monthly, no nocturnal symptoms, FEV1 >80% predicted 3

Step 2 (Mild Persistent):

  • Continue as-needed low-dose ICS-formoterol only
  • This significantly reduces moderate-to-severe exacerbations versus SABA monotherapy 3, 2

Step 3 (Moderate Persistent):

  • Daily maintenance low-dose ICS-formoterol PLUS as-needed ICS-formoterol (MART regimen)
  • Adding long-acting beta2-agonist (LABA) to ICS consistently improves symptoms better than doubling ICS dose 4, 5

Step 4 (Moderate-to-Severe):

  • Increase to medium-dose ICS-formoterol maintenance plus as-needed ICS-formoterol
  • Consider adding long-acting muscarinic antagonist (LAMA) as triple therapy 4, 3

Step 5 (Severe Uncontrolled):

  • High-dose ICS-formoterol maintenance plus as-needed ICS-formoterol
  • Add biologic therapy for type 2 inflammation (elevated eosinophils ≥150/μl, FeNO ≥35 ppb, or elevated IgE) 3
  • Consider low-dose azithromycin (250-500 mg three times weekly) for persistent symptoms 3
  • Low-dose oral corticosteroids (≤7.5 mg/day prednisone equivalent) only as last resort 3

Alternative Treatment Approach: Track 2

If ICS-formoterol is unavailable, use separate inhalers:

  • Daily ICS (low-dose at Step 2, medium-dose at Step 3, high-dose at Steps 4-5)
  • Add separate LABA at Step 3 and above 4
  • As-needed SABA for symptom relief (though this carries higher exacerbation risk than Track 1) 2

Critical Monitoring Requirements

Assess every 2-4 weeks initially, then every 1-3 months:

  • Symptom control (daytime symptoms, nighttime awakenings, activity limitation, reliever use)
  • Lung function (FEV1, FEV1/FVC ratio, bronchodilator reversibility)
  • Inhaler technique and adherence at every visit 4, 3
  • Type 2 biomarkers: peripheral blood eosinophils, FeNO, total IgE 3
  • Exacerbation frequency and oral corticosteroid courses 4

Common Pitfalls to Avoid

Never prescribe SABA monotherapy - this increases severe exacerbations and asthma-related deaths 1, 2. Even patients with infrequent symptoms need ICS-containing treatment.

Do not overuse SABA - more than one canister monthly indicates poor control and increased death risk 3. This signals need to step up ICS-containing therapy.

Avoid high-dose ICS without adding LABA first - combination therapy achieves better outcomes than quadrupling ICS dose, with fewer systemic corticosteroid effects 4, 5.

Do not use LABA as monotherapy - patients must continue ICS when taking LABA, as LABA-only treatment increases severe exacerbations 4.

Beware of incorrect inhaler technique - this is the most common cause of treatment failure. Verify technique at every visit before escalating therapy 4, 3.

Severe Asthma Management

Define severe asthma as uncontrolled despite 3+ months of medium-to-high-dose ICS-LABA, after addressing comorbidities and environmental triggers 3.

Before adding biologics, confirm:

  • Correct diagnosis (consider bronchial provocation testing if FEV1 ≥70% predicted) 3
  • Optimal inhaler technique and adherence
  • Treatment of comorbidities (rhinosinusitis, GERD, obesity, anxiety/depression) 4, 3
  • Avoidance of triggers (smoking, occupational exposures, allergens)

Biologic selection for type 2 severe asthma:

  • Anti-IgE (omalizumab): elevated total IgE with allergic sensitization
  • Anti-IL-5/IL-5Rα (mepolizumab, reslizumab, benralizumab): elevated eosinophils ≥150-300/μl
  • Anti-IL-4Rα (dupilumab): elevated eosinophils and/or FeNO, particularly with nasal polyps 3

All biologics reduce exacerbations and allow oral corticosteroid reduction in appropriate phenotypes 3.

Essential Non-Pharmacologic Management

  • Written asthma action plan for all patients 6, 2
  • Trigger avoidance (allergens, irritants, NSAIDs if aspirin-sensitive, beta-blockers) 4
  • Smoking cessation (active and passive exposure)
  • Annual influenza vaccination
  • Consider allergen immunotherapy for HDM-sensitized patients with FEV1 >70% on low-to-medium-dose ICS 3

When to Refer to Specialist

Refer immediately if:

  • Uncontrolled on Step 4 treatment despite correct technique and adherence 3
  • Frequent exacerbations (≥2 oral corticosteroid courses yearly)
  • History of near-fatal asthma or ICU admission
  • Diagnostic uncertainty (elderly, smokers, atypical features) 7
  • Consideration for biologic therapy or bronchial thermoplasty 3

The evidence strongly favors ICS-formoterol as anti-inflammatory reliever therapy over traditional SABA-based regimens, representing the most significant paradigm shift in asthma management in recent years 1, 2.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.